@article{CarmelaVeglianteRoyoPalomeroetal.2011, author = {Carmela Vegliante, Maria and Royo, Cristina and Palomero, Jara and Salaverria, Itziar and Balint, Balazs and Martin-Guerrero, Idoia and Agirre, Xabier and Lujambio, Amaia and Richter, Julia and Xargay-Torrent, Silvia and Bea, Silvia and Hernandez, Luis and Enjuanes, Anna and Jose Calasanz, Maria and Rosenwald, Andreas and Ott, German and Roman-Gomez, Jose and Prosper, Felipe and Esteller, Manel and Jares, Pedro and Siebert, Reiner and Campo, Elias and Martin-Subero, Jose I. and Amador, Virginia}, title = {Epigenetic Activation of SOX11 in Lymphoid Neoplasms by Histone Modifications}, series = {PLoS ONE}, volume = {6}, journal = {PLoS ONE}, number = {6}, doi = {10.1371/journal.pone.0021382}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-135325}, pages = {e21382}, year = {2011}, abstract = {Recent studies have shown aberrant expression of SOX11 in various types of aggressive B-cell neoplasms. To elucidate the molecular mechanisms leading to such deregulation, we performed a comprehensive SOX11 gene expression and epigenetic study in stem cells, normal hematopoietic cells and different lymphoid neoplasms. We observed that SOX11 expression is associated with unmethylated DNA and presence of activating histone marks (H3K9/14Ac and H3K4me3) in embryonic stem cells and some aggressive B-cell neoplasms. In contrast, adult stem cells, normal hematopoietic cells and other lymphoid neoplasms do not express SOX11. Such repression was associated with silencing histone marks H3K9me2 and H3K27me3. The SOX11 promoter of non-malignant cells was consistently unmethylated whereas lymphoid neoplasms with silenced SOX11 tended to acquire DNA hypermethylation. SOX11 silencing in cell lines was reversed by the histone deacetylase inhibitor SAHA but not by the DNA methyltransferase inhibitor AZA. These data indicate that, although DNA hypermethylation of SOX11 is frequent in lymphoid neoplasms, it seems to be functionally inert, as SOX11 is already silenced in the hematopoietic system. In contrast, the pathogenic role of SOX11 is associated with its de novo expression in some aggressive lymphoid malignancies, which is mediated by a shift from inactivating to activating histone modifications.}, language = {en} } @article{OttLohseKlotzetal.1982, author = {Ott, Ilka and Lohse, Martin J. and Klotz, Karl-Norbert and Vogt-Moykopf, Ingolf and Schwabe, Ulrich}, title = {Effects of Adenosine on Histamine Release from Human Lung Fragments}, series = {International Archives of Allergy and Immunology}, volume = {98}, journal = {International Archives of Allergy and Immunology}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-127877}, pages = {50-56}, year = {1982}, abstract = {The actions of adenosine on histamine release of human lung fragments were investigated. Histamine release was stimulated either with the calcium ionophore A 23187 orwith concanavalin A. Adenosine and its analogue 5'-N-ethylcarboxamidoadenosine alone had no significant effect on basal release or on the release elicited by A 23187 or concanavalin A. However, in the presence of the adenosine receptor antagonist 8-[4-[[[[(2-aminoethyl)amino]-carbonyl] methyloxy]-phenyl]-1,3-dipropylaxanthine (XAC), which itself did not affect the release, adenosine increased the stimulated histamine release. On the other hand, in the presence of the nucleoside transport inhibitor S-(p-nitrobenzyl)-6-thioninosine (NBTI), adenosine caused a reduction in stimulated histamine release. NBTI itself caused a stimulation of release. Thus, a stimulatory effect of adenosine was seen in the presence ofXAC, whereas an inhibitory effect was unmasked by NBTI. From these data it is concluded that adenosine exerts two opposing effects on histamine release in the human lung which neutralize each other: it inhibits release via a si te antagonized by XAC, which presumably represents an A2 adenosine receptor, and it stimulates release via a mechanism that is blocked by NBTI, suggesting that adenosine needs to reach the interior of cells to exert this effect. The slight stimulatory effect of NBTI alone demonstrates that trapping intracellularly formed adenosine inside mast cells leads to sufficient concentrations of adenosine to stimulate histamine release. These findings suggest an important bimodal role of adenosine in regulating histamine release in the human lung.}, language = {en} } @article{OttDorschFraunholzetal.2015, author = {Ott, Christine and Dorsch, Eva and Fraunholz, Martin and Straub, Sebastian and Kozjak-Pavlovic, Vera}, title = {Detailed Analysis of the Human Mitochondrial Contact Site Complex Indicate a Hierarchy of Subunits}, series = {PLoS One}, volume = {10}, journal = {PLoS One}, number = {3}, doi = {10.1371/journal.pone.0120213}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-125347}, pages = {e0120213}, year = {2015}, abstract = {Mitochondrial inner membrane folds into cristae, which significantly increase its surface and are important for mitochondrial function. The stability of cristae depends on the mitochondrial contact site (MICOS) complex. In human mitochondria, the inner membrane MICOS complex interacts with the outer membrane sorting and assembly machinery (SAM) complex, to form the mitochondrial intermembrane space bridging complex (MIB). We have created knockdown cell lines of most of the MICOS and MIB components and have used them to study the importance of the individual subunits for the cristae formation and complex stability. We show that the most important subunits of the MIB complex in human mitochondria are Mic60/Mitofilin, Mic19/CHCHD3 and an outer membrane component Sam50. We provide additional proof that ApoO indeed is a subunit of the MICOS and MIB complexes and propose the name Mic23 for this protein. According to our results, Mic25/CHCHD6, Mic27/ApoOL and Mic23/ApoO appear to be periphery subunits of the MICOS complex, because their depletion does not affect cristae morphology or stability of other components.}, language = {en} } @phdthesis{Ott2015, author = {Ott, Martin}, title = {Lautst{\"a}rkereduzierte Magnetresonanztomographie}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-133921}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2015}, abstract = {Messungen mit Magnetresonanztomographen sind seit jeher mit hohen Lautst{\"a}rken verbunden. Deshalb wird das Ger{\"a}t im Volksmund auch als „laute R{\"o}hre" bezeichnet. Bisher wurde das Problem mit Kopfh{\"o}rern, Ohrenst{\"o}pseln und akustischer D{\"a}mmung des MRT-Scanners angegangen. Auch in der Fachliteratur wird das Problem als gegeben angesehen und es werden kaum wissenschaftliche L{\"o}sungsans{\"a}tze zur Lautst{\"a}rkereduktion beschrieben. Das Ziel der vorliegenden Arbeit war es, Bildgebungs-Sequenzen f{\"u}r schwer‑optimierbare Bildkontraste und sogenannte Standard-Kontraste aus dem klinischen Umfeld hinsichtlich der Lautst{\"a}rke zu optimieren. Viele dieser Kontraste k{\"o}nnen bereits mit einfachen Algorithmen wie dem Gradientengl{\"a}ttungsalgorithmus erfolgreich in Hinblick auf die Lautst{\"a}rke optimiert werden. Allerdings existieren auch Sequenzen beziehungsweise Kontraste, die aufgrund ihrer Eigenschaften nicht von einem solchen Algorithmus profitieren k{\"o}nnen. Die Optimierungen und {\"A}nderungen sollten software-seitig erfolgen, das heißt durch {\"A}nderung der Gradientenformen und Datenakquisition. In der Arbeit wurden die grundlegenden Zusammenh{\"a}nge zwischen den verwendeten Ger{\"a}teparametern und der Lautst{\"a}rke untersucht und zudem die physikalischen Ursachen der Lautst{\"a}rkeentwicklung hergeleitet. Diese konnten anhand der Lorentz-Kr{\"a}fte quantitativ beschrieben werden. Somit konnten die Hauptursachen der Lautst{\"a}rkeentwicklung identifiziert werden. Diese sind abh{\"a}ngig von der Gradienten-Steig-Rate, aber auch von der Amplitude der Gradienten. Es konnte gezeigt werden, dass eine Minimierung dieser Gradientenparameter zu einer geringeren Lautst{\"a}rkeentwicklung f{\"u}hrt. Allerdings f{\"u}hrt diese Minimierung in den meisten F{\"a}llen auch zu einer systematischen Verlangsamung des Sequenzablaufs, was das Erreichen bestimmter Echozeiten und Bildkontraste unm{\"o}glich macht. Zu den problematischen Kontrasten bez{\"u}glich der Lautst{\"a}rkereduktion z{\"a}hlten der T1- und PD‑Kontrast einer Turbo-Spin-Echo-Sequenz. Durch die Kombination von mehreren Maßnahmen, wie der Adaption der k-Raum-Akquisition, der HF-Pulse-Parameter und den Gradientenformen, war es m{\"o}glich, die Lautst{\"a}rke in Beispielmessungen um bis zu 16,8 dB(A) zu reduzieren. Wie bei der k{\"u}rzlich ver{\"o}ffentlichten Methode zur Reduktion f{\"u}r die T2‑gewichteten Kontraste, wurde dies zulasten einer Messzeitverl{\"a}ngerung von bis zu 50\% erreicht. Die Endlautst{\"a}rke betrug dabei circa 81 dB(A). Mit der Lautst{\"a}rkeoptimierung der klinisch bedeutsamen T1- und PD‑Kontraste wurde die Palette an leisen, mit der Turbo-Spin-Echo‑Sequenz erzielbaren, Standard-Kontrasten (T1, T2 und PD) nun vervollst{\"a}ndigt. In einem anderen Ansatz wurde die Anwendbarkeit des CAT-Konzepts auf die Lautst{\"a}rkereduktion untersucht. Beim CAT-Konzept wird die Messung in Einzelmessungen mit verschiedenen Parametern unterteilt. Bisher wurde dieser Ansatz zur SAR-Reduktion verwendet. Das Zentrum des k-Raums wird mit einer SAR-intensiven, kontrastgebenden Messung aufgenommen. Der verbleibende Teil des k-Raums wird mit einer SAR-reduzierten, bildstrukturrelevanten Messung aufgenommen. In dieser Arbeit wurde die {\"U}bertragung des CAT-Konzepts auf die Lautst{\"a}rkereduktion untersucht. Anstelle von SAR-intensiven und SAR‑reduzierten Messungen, wurde hier die Unterteilung in „laute" und „leise" Messungen untersucht. Dabei wurden {\"U}berlegungen angestellt, die es f{\"u}r eine Vielzahl an Messungen erm{\"o}glichen, einen großen Teil der Messung leise zu gestalten ohne die Bildqualit{\"a}t oder den Bildkontrast zu ver{\"a}ndern. In einem weiteren Schritt wurden {\"U}berlegungen f{\"u}r die Lautst{\"a}rkereduktion der lauten Messungen vorgestellt. Anschließend wurden f{\"u}r eine GRE- und TSE-Sequenz Optimierungsschritte evaluiert und die Lautst{\"a}rke gemessen. Der hinsichtlich der Lautst{\"a}rkeoptimierung herausforderndste Bildkontrast ist die diffusionsgewichtete Bildgebung. Diese besitzt eine Diffusions-Pr{\"a}paration zur Sichtbarmachung der Diffusivit{\"a}t, bei der die maximal m{\"o}gliche Gradienten-Amplitude verwendet wird. Ebenso werden nach der Pr{\"a}paration die Daten mit einem EPI‑Akquisitionsmodul mit Blip-Gradienten akquiriert, das mit einem charakteristischem „Pfeifton" einhergeht. Zum einen wurden die Gradientenformen konsequent angepasst. Zum anderen wurde eine Segmentierung der k-Raum-Akquisition in Auslese-Richtung verwendet, um die Gradienten‑Steig-Raten zu reduzieren. Auch hier konnte eine deutliche Lautst{\"a}rkereduktion von bis zu 20,0 dB(A) erzielt werden. Dies wurde zulasten einer Messzeitverl{\"a}ngerung von 27\% ‑ 34\% im Vergleich zur Standard-Sequenz erreicht. Durch eine weitere Messzeitverl{\"a}ngerung um bis zu 23\% kann die Lautst{\"a}rke um weitere 0,9 dB(A) reduziert werden. Dabei h{\"a}ngt die genaue Messzeitverl{\"a}ngerung vom verwendeten GRAPPA-Faktor und der Anzahl der Auslese-Segmente ab. Die entstandene Sequenz wurde in mehreren Kliniken erfolgreich erprobt. Bisher mussten bei MRT-Messungen stets Kompromisse zwischen „hoher Aufl{\"o}sung", „hohem SNR" und „geringer Messzeit" getroffen werden. Als Anschauung daf{\"u}r wurde das „Bermuda‑Dreieck der MRT" eingef{\"u}hrt. Da alle drei Gr{\"o}ßen sich gegenseitig ausschließen, muss stets ein Mittelweg gefunden werden. Einige der in dieser Arbeit erzielten Erfolge bei der Lautst{\"a}rkereduktion wurden auf Kosten einer verl{\"a}ngerten Messzeit erreicht. Daher ist es naheliegend, das „Bermuda-Dreieck der MRT" um die Dimension der „geringen Lautst{\"a}rke" zu einer „Bermuda-Pyramide der MRT" zu erweitern. Damit muss die Lautst{\"a}rkeentwicklung in die Mittelweg‑Findung miteinbezogen werden. Die in dieser Arbeit erzielten Lautst{\"a}rken liegen in der Gr{\"o}ßenordnung zwischen 80 ‑ 85 dB(A). Somit k{\"o}nnen Messungen bei Verwendung von Geh{\"o}rschutz angenehm f{\"u}r den Patienten durchgef{\"u}hrt werden. Durch neue Techniken der Zukunft wird es wahrscheinlich sein, h{\"o}here Aufl{\"o}sungen, h{\"o}heres SNR oder k{\"u}rzere Aufnahmedauern zu erzielen, beziehungsweise stattdessen diese in eine geringe Lautst{\"a}rke „umzuwandeln". Ebenso werden m{\"o}glicherweise auf der hardware-technischen Seite Fortschritte erzielt werden, so dass in neueren MRT-Scannergenerationen mehr Wert auf die L{\"a}rmd{\"a}mmung gelegt wird und somit der softwarebasierten Lautst{\"a}rkereduktion einen Schritt entgegen gekommen wird. Damit k{\"o}nnten zuk{\"u}nftige Patienten-Messungen g{\"a}nzlich ohne st{\"o}renden Geh{\"o}rschutz durchgef{\"u}hrt werden.}, subject = {Kernspintomografie}, language = {de} } @incollection{LohseKlotzMaureretal.1990, author = {Lohse, Martin J. and Klotz, Karl-Norbert and Maurer, K. and Ott, I. and Schwabe, Ulrich}, title = {Effects of adenosine on mast cells}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-86101}, publisher = {Universit{\"a}t W{\"u}rzburg}, year = {1990}, abstract = {No abstract available}, subject = {Adenosin}, language = {en} } @article{DumontWeberLassalleJolyBeauparlantetal.2022, author = {Dumont, Martine and Weber-Lassalle, Nana and Joly-Beauparlant, Charles and Ernst, Corinna and Droit, Arnaud and Feng, Bing-Jian and Dubois, St{\´e}phane and Collin-Deschesnes, Annie-Claude and Soucy, Penny and Vall{\´e}e, Maxime and Fournier, Fr{\´e}d{\´e}ric and Lema{\c{c}}on, Audrey and Adank, Muriel A. and Allen, Jamie and Altm{\"u}ller, Janine and Arnold, Norbert and Ausems, Margreet G. E. M. and Berutti, Riccardo and Bolla, Manjeet K. and Bull, Shelley and Carvalho, Sara and Cornelissen, Sten and Dufault, Michael R. and Dunning, Alison M. and Engel, Christoph and Gehrig, Andrea and Geurts-Giele, Willemina R. R. and Gieger, Christian and Green, Jessica and Hackmann, Karl and Helmy, Mohamed and Hentschel, Julia and Hogervorst, Frans B. L. and Hollestelle, Antoinette and Hooning, Maartje J. and Horv{\´a}th, Judit and Ikram, M. Arfan and Kaulfuß, Silke and Keeman, Renske and Kuang, Da and Luccarini, Craig and Maier, Wolfgang and Martens, John W. M. and Niederacher, Dieter and N{\"u}rnberg, Peter and Ott, Claus-Eric and Peters, Annette and Pharoah, Paul D. P. and Ramirez, Alfredo and Ramser, Juliane and Riedel-Heller, Steffi and Schmidt, Gunnar and Shah, Mitul and Scherer, Martin and St{\"a}bler, Antje and Strom, Tim M. and Sutter, Christian and Thiele, Holger and van Asperen, Christi J. and van der Kolk, Lizet and van der Luijt, Rob B. and Volk, Alexander E. and Wagner, Michael and Waisfisz, Quinten and Wang, Qin and Wang-Gohrke, Shan and Weber, Bernhard H. F. and Devilee, Peter and Tavtigian, Sean and Bader, Gary D. and Meindl, Alfons and Goldgar, David E. and Andrulis, Irene L. and Schmutzler, Rita K. and Easton, Douglas F. and Schmidt, Marjanka K. and Hahnen, Eric and Simard, Jacques}, title = {Uncovering the contribution of moderate-penetrance susceptibility genes to breast cancer by whole-exome sequencing and targeted enrichment sequencing of candidate genes in women of European ancestry}, series = {Cancers}, volume = {14}, journal = {Cancers}, number = {14}, issn = {2072-6694}, doi = {10.3390/cancers14143363}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-281768}, year = {2022}, abstract = {Rare variants in at least 10 genes, including BRCA1, BRCA2, PALB2, ATM, and CHEK2, are associated with increased risk of breast cancer; however, these variants, in combination with common variants identified through genome-wide association studies, explain only a fraction of the familial aggregation of the disease. To identify further susceptibility genes, we performed a two-stage whole-exome sequencing study. In the discovery stage, samples from 1528 breast cancer cases enriched for breast cancer susceptibility and 3733 geographically matched unaffected controls were sequenced. Using five different filtering and gene prioritization strategies, 198 genes were selected for further validation. These genes, and a panel of 32 known or suspected breast cancer susceptibility genes, were assessed in a validation set of 6211 cases and 6019 controls for their association with risk of breast cancer overall, and by estrogen receptor (ER) disease subtypes, using gene burden tests applied to loss-of-function and rare missense variants. Twenty genes showed nominal evidence of association (p-value < 0.05) with either overall or subtype-specific breast cancer. Our study had the statistical power to detect susceptibility genes with effect sizes similar to ATM, CHEK2, and PALB2, however, it was underpowered to identify genes in which susceptibility variants are rarer or confer smaller effect sizes. Larger sample sizes would be required in order to identify such genes.}, language = {en} } @article{LoefflerWirthKreuzHoppetal.2019, author = {Loeffler-Wirth, Henry and Kreuz, Markus and Hopp, Lydia and Arakelyan, Arsen and Haake, Andrea and Cogliatti, Sergio B. and Feller, Alfred C. and Hansmann, Martin-Leo and Lenze, Dido and M{\"o}ller, Peter and M{\"u}ller-Hermelink, Hans Konrad and Fortenbacher, Erik and Willscher, Edith and Ott, German and Rosenwald, Andreas and Pott, Christiane and Schwaenen, Carsten and Trautmann, Heiko and Wessendorf, Swen and Stein, Harald and Szczepanowski, Monika and Tr{\"u}mper, Lorenz and Hummel, Michael and Klapper, Wolfram and Siebert, Reiner and Loeffler, Markus and Binder, Hans}, title = {A modular transcriptome map of mature B cell lymphomas}, series = {Genome Medicine}, volume = {11}, journal = {Genome Medicine}, doi = {10.1186/s13073-019-0637-7}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-237262}, year = {2019}, abstract = {Background Germinal center-derived B cell lymphomas are tumors of the lymphoid tissues representing one of the most heterogeneous malignancies. Here we characterize the variety of transcriptomic phenotypes of this disease based on 873 biopsy specimens collected in the German Cancer Aid MMML (Molecular Mechanisms in Malignant Lymphoma) consortium. They include diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt's lymphoma, mixed FL/DLBCL lymphomas, primary mediastinal large B cell lymphoma, multiple myeloma, IRF4-rearranged large cell lymphoma, MYC-negative Burkitt-like lymphoma with chr. 11q aberration and mantle cell lymphoma. Methods We apply self-organizing map (SOM) machine learning to microarray-derived expression data to generate a holistic view on the transcriptome landscape of lymphomas, to describe the multidimensional nature of gene regulation and to pursue a modular view on co-expression. Expression data were complemented by pathological, genetic and clinical characteristics. Results We present a transcriptome map of B cell lymphomas that allows visual comparison between the SOM portraits of different lymphoma strata and individual cases. It decomposes into one dozen modules of co-expressed genes related to different functional categories, to genetic defects and to the pathogenesis of lymphomas. On a molecular level, this disease rather forms a continuum of expression states than clearly separated phenotypes. We introduced the concept of combinatorial pattern types (PATs) that stratifies the lymphomas into nine PAT groups and, on a coarser level, into five prominent cancer hallmark types with proliferation, inflammation and stroma signatures. Inflammation signatures in combination with healthy B cell and tonsil characteristics associate with better overall survival rates, while proliferation in combination with inflammation and plasma cell characteristics worsens it. A phenotypic similarity tree is presented that reveals possible progression paths along the transcriptional dimensions. Our analysis provided a novel look on the transition range between FL and DLBCL, on DLBCL with poor prognosis showing expression patterns resembling that of Burkitt's lymphoma and particularly on 'double-hit' MYC and BCL2 transformed lymphomas. Conclusions The transcriptome map provides a tool that aggregates, refines and visualizes the data collected in the MMML study and interprets them in the light of previous knowledge to provide orientation and support in current and future studies on lymphomas and on other cancer entities.}, language = {en} } @article{HartmannPluetschowMottoketal.2019, author = {Hartmann, Sylvia and Pl{\"u}tschow, Annette and Mottok, Anja and Bernd, Heinz-Wolfram and Feller, Alfred C. and Ott, German and Cogliatti, Sergio and Fend, Falko and Quintanilla-Martinez, Leticia and Stein, Harald and Klapper, Wolfram and M{\"o}ller, Peter and Rosenwald, Andreas and Engert, Andreas and Hansmann, Martin-Leo and Eichenauer, Dennis A.}, title = {The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma}, series = {American Journal of Hematology}, volume = {94}, journal = {American Journal of Hematology}, number = {11}, doi = {10.1002/ajh.25607}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-212594}, pages = {1208 -- 1213}, year = {2019}, abstract = {Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) can present with different histopathological growth patterns. The impact of these histopathological growth patterns on relapse characteristics is unknown. We therefore analyzed paired biopsies obtained at initial diagnosis and relapse from 33 NLPHL patients who had received first-line treatment within German Hodgkin Study Group (GHSG) trial protocols, and from a second cohort of 41 relapsed NLPHL patients who had been treated outside GHSG studies. Among the 33 GHSG patients, 21 patients presented with a typical growth pattern at initial diagnosis, whereas 12 patients had a variant histology. The histopathological growth patterns at initial diagnosis and at relapse were consistent in 67\% of cases. A variant histology at initial diagnosis was associated with a shorter median time to lymphoma recurrence (2.8 vs 5.2 years; P = .0219). A similar tendency towards a shorter median time to lymphoma recurrence was observed for patients presenting with a variant histology at relapse, irrespective of the growth pattern at initial diagnosis. Results obtained from the 41 NLPHL patients who had been treated outside GHSG studies were comparable (median time to lymphoma recurrence for variant histology vs typical growth pattern at initial diagnosis: 1.5 vs 7.0 years). In conclusion, the histopathological growth pattern remains consistent at relapse in the majority of NLPHL cases, and has major impact on the time of relapse.}, language = {en} }